Literature DB >> 33237349

Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10.

Boxing Su1, Haibo Han2, Yanqing Gong3,4, Xuesong Li3,4, Chaoyue Ji5, Jingjing Yao6, Jianghui Yang6, Weiguo Hu5, Wei Zhao7, Jianxing Li5, Gang Zhang8, Liqun Zhou9,10.   

Abstract

The microRNA let-7d has been reported to be a tumor suppressor in renal cell carcinoma (RCC). Tumor-associated macrophages (TAM) are M2-polarized macrophages that can enhance tumor growth and angiogenesis in many human cancers. However, the role of let-7d in TAM-associated RCC progression remains elusive. First, we observed a strongly inverse correlation between let-7d expression and microvessel density in RCC tissues. Furthermore, the proliferation, migration, and tube formation of HUVECs were significantly inhibited by conditioned medium from a coculture system of the phorbol myristate acetate pretreated human THP-1 macrophages and let-7d-overexpressing RCC cells. Moreover, the proportion of M2 macrophages was significantly lower in the group that was cocultured with let-7d-overexpressing RCC cells. Subcutaneous xenografts formed by the injection of let-7d-overexpressing RCC cells together with THP-1 cells resulted in a significant decrease in the M2 macrophage ratio and microvessel density compared with those formed by the injection of control RCC cells with THP-1 cells. In silico and experimental analysis revealed interleukin-10 (IL-10) and IL-13 as let-7d target genes. Importantly, the addition of IL-10 and IL-13 counteracted the inhibitory effects of the conditioned medium from the coculture system with let-7d-overexpressing RCC cells in vitro. Additionally, overexpression of IL-10 and IL-13 reversed the effects of let-7d on macrophage M2 polarization and tumor angiogenesis in vivo. Finally, the expression of IL-10 and IL-13 were inversely correlated with the expression of let-7d in RCC clinical specimens. These results suggest that let-7d may inhibit intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-10 and IL-13.

Entities:  

Keywords:  Angiogenesis; IL-10; IL-13; Let-7d; Macrophage; microRNA

Mesh:

Substances:

Year:  2020        PMID: 33237349     DOI: 10.1007/s00262-020-02791-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Chronic psychological stress alters gene expression in rat colon epithelial cells promoting chromatin remodeling, barrier dysfunction and inflammation.

Authors:  John W Wiley; Gerald A Higgins; Shuangsong Hong
Journal:  PeerJ       Date:  2022-04-29       Impact factor: 3.061

2.  A crosstalk between type 2 innate lymphoid cells and alternative macrophages in lung development and lung diseases (Review).

Authors:  Lan-Lan Mi; Yue Zhu; Hong-Yan Lu
Journal:  Mol Med Rep       Date:  2021-03-31       Impact factor: 2.952

3.  TNFSF9 promotes metastasis of pancreatic cancer through Wnt/Snail signaling and M2 polarization of macrophages.

Authors:  Jiao Wu; Yunpeng Wang; Yichun Yang; Fuqiang Liu; Jun Chen; Zhongxiang Jiang; Zheng Jiang
Journal:  Aging (Albany NY)       Date:  2021-09-13       Impact factor: 5.682

4.  Diagnostic Potential of Plasma Extracellular Vesicle miR-483-3p and Let-7d-3p for Sepsis.

Authors:  Guanguan Qiu; Jiajie Fan; Guoping Zheng; Jiangping He; Fangping Lin; Menghua Ge; Lanfang Huang; Jiangmei Wang; Jie Xia; Ruoqiong Huang; Qiang Shu; Jianguo Xu
Journal:  Front Mol Biosci       Date:  2022-02-02

Review 5.  Macrophages, as a Promising Strategy to Targeted Treatment for Colorectal Cancer Metastasis in Tumor Immune Microenvironment.

Authors:  Yingru Zhang; Yiyang Zhao; Qi Li; Yan Wang
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

Review 6.  Therapeutic Approaches Targeting Proteins in Tumor-Associated Macrophages and Their Applications in Cancers.

Authors:  Deyang Wu; Xiaowei Liu; Jingtian Mu; Jin Yang; Fanglong Wu; Hongmei Zhou
Journal:  Biomolecules       Date:  2022-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.